ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Melanoma

Triple Negative Breast Cancer trials near San Francisco, CA, USA:

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

San Francisco, California, United States and 44 other locations

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Atezolizumab
Drug: Sacituzumab govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

San Francisco, California, United States and 8 other locations

avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...

Enrolling
Stage IIIA Breast Cancer
Recurrent Breast Carcinoma
Biological: Utomilumab
Biological: Anti-OX40 Antibody PF-04518600

Phase 2

Hope Rugo, MD

San Francisco, California, United States and 11 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

San Francisco, California, United States and 131 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Niraparib
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

San Francisco, California, United States and 226 other locations

This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO)...

Active, not recruiting
Triple Negative Breast Cancer
Biological: Pembrolizumab
Device: Immunopulse

Phase 2

OncoSec Medical

Palo Alto, California, United States and 13 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Tobemstomig

Phase 2

Roche
Roche

San Francisco, California, United States and 85 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Santa Rosa, California, United States and 508 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Enrolling
Breast Cancer
Drug: Carboplatin
Drug: Nab-paclitaxel

Phase 3

AstraZeneca
AstraZeneca

San Francisco, California, United States and 273 other locations

after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

San Francisco, California, United States and 121 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems